Infectious Disease

Raffi Aroian of the University of California, San Diego in the U.S. proposes to develop a delivery system for non-toxic, anti-roundworm proteins. With this system, mass production of a safe, potent cure for intestinal Roundworms that is cheap and compatible with global distribution should be possible. This project's Phase I research demonstrated that an anthelmintic protein could be expressed in three food-grade bacterial strains safe for humans.

Ali Salanti of the University of Copenhagen in Denmark will develop and test a vaccine combining a new placental malaria vaccine candidate with the cervical cancer vaccine, with the potential of inducing a strong protective response against both diseases simultaneously. This project's Phase I research demonstrated that a combinatorial HPV and placental malaria vaccine induced highly functioning antibodies relevant to both diseases.

Ekaterina Dadachova of the Albert Einstein College of Medicine in the U.S., in collaboration with Arturo Casadevall, proposes to use radioimmunotherapy as a strategy to eliminate HIV-infected cells in patients on anti-retroviral therapy. Targeting viral antigens on these cells with radioactivity-armed antibodies could lead to HIV eradication. This project's Phase I research demonstrated that radioimmunotherapy can kill HIV-infected primary human cells in conjunction with anti-retroviral therapy (ART) and that this antibody can also reach HIV-infected cells in the central nervous system.

Juliana Cassataro of the Universidad Nacional de San Martí­n-CONICET in Argentina will test whether the bacterial protease inhibitor Omp19 can make vaccines more effective when they are administered orally. Oral delivery of vaccines is far simpler than by injection, which is particularly useful in low-resource settings, and it may also stimulate mucosal immunity making them more effective against some diseases. However, most vaccines administered orally are degraded in the stomach or do not induce a sufficient immune response to protect against the disease.

Juliana Cassataro of the Universidad Nacional de San Martín-CONICET in Argentina will test whether the bacterial protease inhibitor Omp19 can make vaccines more effective when they are administered orally. Oral delivery of vaccines is far simpler than by injection, which is particularly useful in low-resource settings, and it may also stimulate mucosal immunity making them more effective against some diseases. However, most vaccines administered orally are degraded in the stomach or do not induce a sufficient immune response to protect against the disease.

Jennifer Doudna of the University of California, Berkeley in the U.S. test the ability of newly discovered RNA restriction enzymes to bind to specific RNA sequences inherent in a wide range of pathogens. If successful, this test could potentially be embedded on wickable paper to test human urine samples and produce a colormetric readout diagnostic like a pregnancy test.

Filippo Mancia of Columbia University in the U.S. will perform crystallization experiments on a key olfactory receptor used by mosquitoes to detect humans. The aim of these studies is to determine at an atomic level the conserved regions on the olfactory receptor in order to develop drug therapies to block these receptors. This project's Phase I research generated diffraction quality crystals of this targeted mosquito olfactory receptor, and in Phase II, the team will optimize the crystal to determine the structure of the receptor and how it binds to small molecule anti-malarial compounds.

Consuelo De Moraes, Mark Mescher and Andrew Read of Pennsylvania State University in the U.S. will test the theory that malaria infection induces characteristic odor cues, even in asymptomatic individuals. By identifying these chemical cues with gas chromatography and mass spectrometry, De Moraes will determine if there are biomarkers for diagnosis of infection.

Rebecca Richards-Kortum of Rice University in the U.S. will measure light scattered by malaria-infected red blood cells using a small microscope that can be placed on the skin as a way to detect infection in patients without the need to draw blood. This rapid and painless diagnostic would not require consumable reagents or a trained operator, and would not generate biohazardous waste.

Elizabeth Ryan of Colorado State University in the U.S. will screen a diverse, global set of rice varieties to identify bioactive components in the bran that augment mucosal immunity against enteric bacterial pathogens. In this project's Phase I research, Ryan and her team identified multiple mechanisms of mucosal immune induction and demonstrated that increased dietary rice bran intake reduces host susceptibility to enteric infections via enhanced gut mucosal immunity.